BAKER BROS. ADVISORS LP Q2 2019 Filing
Filed August 14, 2019
Portfolio Value
$14.7B
Holdings
103
Report Date
Q2 2019
Filing Type
13F-HR
All Holdings (103 positions)
| Stock | Value |
|---|---|
SGENEURSeattle Genetics, Inc. | $3.5B |
INCYIncyte Corporation | $2.7B |
ONCBeiGene, Ltd. | $1.5B |
ALXNAlexion Pharmaceuticals, Inc. | $1.1B |
ACADACADIA Pharmaceuticals Inc. | $1.1B |
AMRNAmarin Corporation plc | $805.5M |
BMRNBioMarin Pharmaceutical Inc. | $650.0M |
—Genomic Health, Inc. | $538.7M |
ASNDAscendis Pharma A/S | $390.4M |
MRTXEURMirati Therapeutics, Inc. | $258.9M |
ARGXargenx SE | $144.3M |
ARRYEURArray BioPharma Inc. | $132.0M |
MDGLMadrigal Pharmaceuticals, Inc. | $122.6M |
NBIXNeurocrine Biosciences, Inc. | $119.5M |
HRTXHeron Therapeutics, Inc. | $111.9M |
KODKodiak Sciences, Inc. | $107.0M |
NVTA1EURInvitae Corporation | $91.7M |
1T7Tricida, Inc. | $77.7M |
—Spark Therapeutics, Inc. | $77.0M |
BCELAtreca, Inc. | $66.6M |
—GW Pharmaceuticals plc | $63.9M |
IM8NInsmed Incorporated | $63.0M |
CERSCerus Corporation | $60.4M |
RYTMRhythm Pharmaceuticals, Inc. | $59.6M |
—Principia Biopharma Inc. | $59.3M |
—Audentes Therapeutics, Inc. | $57.0M |
ADPTAdaptive Biotechnologies Corporation | $56.3M |
BCRXBioCryst Pharmaceuticals, Inc. | $54.5M |
—Ra Pharmaceuticals, Inc. | $54.2M |
—MyoKardia, Inc. | $51.0M |
—DBV Technologies S.A. | $45.3M |
KRYSKrystal Biotech, Inc. | $41.7M |
CBAYUSDCymaBay Therapeutics, Inc. | $40.9M |
NBIX 2.25 05/15/24Neurocrine Biosciences, Inc. | $40.5M |
QUREuniQure N.V. | $40.5M |
KNSAKiniksa Pharmaceuticals, Ltd. | $37.9M |
—Zymeworks Inc. | $37.6M |
—Aquinox Pharmaceuticals, Inc. | $25.8M |
AXSMAxsome Therapeutics, Inc. | $19.9M |
XNCRXencor, Inc. | $17.5M |
MRUSMerus N.V. | $17.0M |
BMRN 0.599 08/01/24BioMarin Pharmaceutical Inc. | $15.6M |
—Acorda Therapeutics, Inc. | $15.4M |
—La Jolla Pharmaceutical Company | $14.4M |
—Aimmune Therapeutics, Inc. | $14.0M |
—Idera Pharmaceuticals, Inc. | $12.3M |
PTGXProtagonist Therapeutics, Inc. | $12.1M |
TPIVDEURMarker Therapeutics, Inc. | $11.9M |
AGLEUSDAeglea BioTherapeutics, Inc. | $11.7M |
ASMBAssembly Biosciences, Inc. | $10.8M |
GBYSangamo Therapeutics, Inc. | $10.8M |
CPRXCatalyst Pharmaceuticals, Inc. | $9.8M |
—Syros Pharmaceuticals, Inc. | $9.0M |
ALKSAlkermes plc | $9.0M |
—Dermira, Inc. | $8.7M |
BDQMAlbireo Pharma, Inc. | $8.1M |
APLSApellis Pharmaceuticals, Inc. | $8.0M |
MISTMilestone Pharmaceuticals Inc. | $7.2M |
ANABAnaptysBio, Inc. | $6.4M |
—Abeona Therapeutics Inc. | $6.2M |
HOOKGBPHOOKIPA Pharma Inc. | $6.0M |
ORTXUSDOrchard Therapeutics plc | $5.7M |
HALOHalozyme Therapeutics, Inc. | $5.2M |
—bluebird bio, Inc. | $5.1M |
—Bellicum Pharmaceuticals, Inc. | $4.6M |
—Menlo Therapeutics Inc. | $4.2M |
GTHXEURG1 Therapeutics, Inc. | $3.9M |
NGMUSDNGM Biopharmaceuticals, Inc. | $3.7M |
VKTXViking Therapeutics, Inc. | $3.5M |
XLRNAcceleron Pharma Inc. | $3.4M |
CRNXCrinetics Pharmaceuticals, Inc. | $3.3M |
GLPGGalapagos NV | $3.2M |
—Achillion Pharmaceuticals, Inc. | $2.9M |
VSAREURAravive, Inc. | $2.9M |
XBITXBiotech Inc. | $2.9M |
—Harpoon Therapeutics, Inc. | $2.8M |
—Forty Seven, Inc. | $2.6M |
AUTLAutolus Therapeutics plc | $2.5M |
YMABUSDY-mAbs Therapeutics, Inc. | $2.4M |
—Cyclerion Therapeutics, Inc. | $2.3M |
—Spring Bank Pharmaceuticals, Inc. | $2.3M |
NXTCNextCure, Inc. | $2.2M |
CTMXCytomX Therapeutics, Inc. | $2.2M |
—Molecular Templates, Inc. | $2.1M |
NTLAIntellia Therapeutics, Inc. | $2.1M |
IDYAIDEAYA Biosciences, Inc. | $2.0M |
CCXIEURChemoCentryx, Inc. | $1.9M |
—Constellation Pharmaceuticals, Inc. | $1.6M |
GLMDGalmed Pharmaceuticals Ltd. | $1.6M |
—Aileron Therapeutics, Inc. | $1.5M |
—Dova Pharmaceuticals, Inc. | $1.4M |
—Foamix Pharmaceuticals Ltd. | $1.2M |
—Sierra Oncology, Inc. | $1.1M |
—Adamas Pharmaceuticals, Inc. | $1.1M |
INFIQInfinity Pharmaceuticals, Inc. | $1.0M |
RCUSArcus Biosciences, Inc. | $966K |
FLGTFulgent Genetics, Inc. | $835K |
—Affimed N.V. | $574K |
AQSTAquestive Therapeutics, Inc. | $418K |
—Sunesis Pharmaceuticals, Inc. | $405K |
Page 1 of 2Next